ON7 7-Hydroxy 3X 30MG 10pk 3ct
The ON7 7-Hydroxy 3X 30MG 10pk 3ct is a high-potency chewable tablet product designed for adult retail environments such as smoke shops, specialty wellness stores, and extract-focused merchandising. Each display includes 10 individual packs, with 3 tablets per pack, delivering 30 mg of 7-hydroxymitragynine per tablet, a concentrated alkaloid derived from Mitragyna speciosa known for its strong potency and fast-acting profile. The chewable tablet format allows for rapid absorption, precise dosing, and convenient on-the-go use, making it ideal for wholesale distribution and structured retail display systems.

This product is packaged in a compact multi-pack display format optimized for shelf visibility, inventory control, and high-turnover retail environments. The “3X” formulation positions it within the enhanced potency segment, appealing to experienced consumers seeking efficient, fast-acting alternatives to traditional kratom powders or capsules. Flavor-forward chewable options (such as fruit profiles) further improve user experience while maintaining strong retail appeal and differentiation in competitive extract categories.

As demand continues to grow for 7-hydroxy extract products and advanced alkaloid formulations, this SKU provides retailers with a scalable, high-margin option. The combination of 30 mg strength, 3-count packs, and 10-pack display configuration supports repeat purchasing behavior, flexible pricing strategies, and strong shelf performance, making it a valuable addition to wholesale assortments focused on high-potency botanical extracts and functional alkaloid products.
WARNING
• 21+ only — adult use only
• High-potency extract product
• Keep out of reach of children and pets
• For retail sale and display only
• Follow local and state regulations
NOTE: Products containing kratom or concentrated 7-hydroxymitragynine are not evaluated or approved by the FDA and may carry significant health risks. 7-hydroxymitragynine is a biologically active compound with strong activity at opioid receptors and substantially higher potency compared to mitragynine. These products may be restricted or regulated in certain jurisdictions, and retailers and consumers are responsible for complying with all applicable laws and regulations.



